Immunology Investor Event
Rilzabrutinib and Topical BTKi positioned to address
earlier stage Atopic Dermatitis
Innate Immune
Mast Cell/
Eosinophil
IgE-mediated FCER activation
and degranulation
BTK signaling
BTK signaling
Macrophage
BTK signaling
Inflammation
and
Tissue
Damage
BTK signaling
IgG-mediated FcyR activation,
phagocytosis, inflammatory
mediators
BTK signaling
BTK signaling
Neutrophil
Activation, adhesion,
recruitment, oxidative burst
sanofi
Adaptive Immune
Autoreactive
B Cell
Long-Lived
Plasma Cell
Plasma cell differentiation
and antibody production
Topical BTKI
(SAR444727)
Phase 2 study readout
in H1 2023
rilzabrutinib
Phase 2 study in
moderate to severe AD
Readout in H1 2023
Rilzabrutinib and topical BTKI are currently under clinical investigation, and their safety and efficacy have not been evaluated by any regulatory authority
35 Immunology Investor Event
Autoantibodies
IgEView entire presentation